PCS-话题@MedSci - 梅斯（MedSci）

#PCS#

107篇内容 | 3262人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1685634, encodeId=dfbe168563481, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, objectTitle=诺华与英国NHS联合，以快速推进胆固醇PCSK9的基因干扰药物inclisiran, objectType=article, longId=186391, objectId=6e90186391ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e90186391ad, replyNumber=0, likeNumber=113, createdTime=2020-09-17, rootId=0, userName=Tamikia, userId=173d28230918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e90186391ad, moduleTitle=诺华与英国NHS联合，以快速推进胆固醇PCSK9的基因干扰药物inclisiran, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=6e90186391ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685644, encodeId=f54a168564499, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, objectTitle=JAMA Cardiology：与他汀类药物和依折麦布相比，PCSK9抑制剂降低LDL-C的效果更显著, objectType=article, longId=203418, objectId=ecf82034184f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ecf82034184f, replyNumber=0, likeNumber=78, createdTime=2021-04-20, rootId=0, userName=Tamikia, userId=173d28230918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ecf82034184f, moduleTitle=JAMA Cardiology：与他汀类药物和依折麦布相比，PCSK9抑制剂降低LDL-C的效果更显著, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ecf82034184f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685638, encodeId=8e281685638eb, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, objectTitle=Circulation：PCSK9抑制对静脉血栓栓塞（VTE）风险的影响, objectType=article, longId=195335, objectId=8002195335e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8002195335e0, replyNumber=0, likeNumber=89, createdTime=2021-04-23, rootId=0, userName=Tamikia, userId=173d28230918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8002195335e0, moduleTitle=Circulation：PCSK9抑制对静脉血栓栓塞（VTE）风险的影响, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=8002195335e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685633, encodeId=bfbb1685633e9, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, objectTitle=诺华97亿收购的PCSK9的siRNA药物inclisiran，预计将于2020年批准上市, objectType=article, longId=185939, objectId=005818593917, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=005818593917, replyNumber=0, likeNumber=83, createdTime=2020-10-24, rootId=0, userName=Tamikia, userId=173d28230918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=005818593917, moduleTitle=诺华97亿收购的PCSK9的siRNA药物inclisiran，预计将于2020年批准上市, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=005818593917)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685639, encodeId=d9951685639e8, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, objectTitle=JAHA：PCSK9抑制剂可改善HIV携带者冠脉健康, objectType=article, longId=197806, objectId=93af19e80665, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93af19e80665, replyNumber=0, likeNumber=106, createdTime=2021-01-19, rootId=0, userName=Tamikia, userId=173d28230918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93af19e80665, moduleTitle=JAHA：PCSK9抑制剂可改善HIV携带者冠脉健康, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=93af19e80665)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685630, encodeId=6779168563044, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, objectTitle=Curr Atheroscle Rep：从机制到实践，PCSK9抑制剂成为降脂治疗新选择, objectType=article, longId=180194, objectId=6961180194ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6961180194ec, replyNumber=0, likeNumber=0, createdTime=2019-11-25, rootId=0, userName=Tamikia, userId=173d28230918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6961180194ec, moduleTitle=Curr Atheroscle Rep：从机制到实践，PCSK9抑制剂成为降脂治疗新选择, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=6961180194ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685631, encodeId=cbd1168563145, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, objectTitle=诺华宣布以97亿美元收购The Medicines Company，同时获得PCSK9的siRNA抑制剂, objectType=article, longId=184019, objectId=daf618401931, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=daf618401931, replyNumber=0, likeNumber=78, createdTime=2020-03-29, rootId=0, userName=Tamikia, userId=173d28230918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=daf618401931, moduleTitle=诺华宣布以97亿美元收购The Medicines Company，同时获得PCSK9的siRNA抑制剂, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=daf618401931)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685627, encodeId=ab16168562e06, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, objectTitle=Medicines公司的一年两次PCSK9抑制剂抗动脉粥样硬化达到III期研究的主要目标, objectType=article, longId=178240, objectId=d4021e824003, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4021e824003, replyNumber=0, likeNumber=75, createdTime=2020-05-07, rootId=0, userName=Tamikia, userId=173d28230918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4021e824003, moduleTitle=Medicines公司的一年两次PCSK9抑制剂抗动脉粥样硬化达到III期研究的主要目标, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d4021e824003)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685635, encodeId=b28c1685635d4, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, objectTitle=NEJM:PCSK9抑制剂 InclisiranIII期临床效果显著, objectType=article, longId=190422, objectId=cfc8190422fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cfc8190422fa, replyNumber=0, likeNumber=67, createdTime=2020-12-31, rootId=0, userName=Tamikia, userId=173d28230918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cfc8190422fa, moduleTitle=NEJM:PCSK9抑制剂 InclisiranIII期临床效果显著, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=cfc8190422fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685629, encodeId=1c4d168562927, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, objectTitle=Clinica Chimica Acta：患有代谢综合征的绝经后妇女的循环PCSK9浓度出现增加?, objectType=article, longId=179435, objectId=99741e9435ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=99741e9435ba, replyNumber=0, likeNumber=92, createdTime=2020-04-26, rootId=0, userName=Tamikia, userId=173d28230918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=99741e9435ba, moduleTitle=Clinica Chimica Acta：患有代谢综合征的绝经后妇女的循环PCSK9浓度出现增加?, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=99741e9435ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685623, encodeId=389d1685623e3, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, objectTitle=Neurology:“坏胆固醇LDL-C越低越好”受质疑，挑战PCSK9抑制剂安全性：Neurology杂志研究称，<70mg/dl脑出血风险增倍, objectType=article, longId=164741, objectId=43c5164e41c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43c5164e41c4, replyNumber=0, likeNumber=76, createdTime=2020-02-02, rootId=0, userName=Tamikia, userId=173d28230918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43c5164e41c4, moduleTitle=Neurology:“坏胆固醇LDL-C越低越好”受质疑，挑战PCSK9抑制剂安全性：Neurology杂志研究称，<70mg/dl脑出血风险增倍, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=43c5164e41c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685628, encodeId=14a0168562882, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, objectTitle=评估PCS-499治疗皮脂腺杆菌的安全性和耐受性, objectType=article, longId=178244, objectId=29201e82446e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29201e82446e, replyNumber=0, likeNumber=69, createdTime=2019-08-30, rootId=0, userName=Tamikia, userId=173d28230918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29201e82446e, moduleTitle=评估PCS-499治疗皮脂腺杆菌的安全性和耐受性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=29201e82446e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685632, encodeId=a380168563214, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, objectTitle=Circulation：PCSK9抑制剂阿利库单抗对急性冠脉综合征患者卒中风险的影响, objectType=article, longId=185077, objectId=c42a1850e7c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c42a1850e7c0, replyNumber=0, likeNumber=78, createdTime=2020-10-28, rootId=0, userName=Tamikia, userId=173d28230918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c42a1850e7c0, moduleTitle=Circulation：PCSK9抑制剂阿利库单抗对急性冠脉综合征患者卒中风险的影响, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c42a1850e7c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685624, encodeId=7647168562410, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, objectTitle=JACC：PCSK9抑制剂对慢性肾脏疾病的影响, objectType=article, longId=169024, objectId=3826169024c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3826169024c3, replyNumber=0, likeNumber=0, createdTime=2019-07-16, rootId=0, userName=Tamikia, userId=173d28230918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3826169024c3, moduleTitle=JACC：PCSK9抑制剂对慢性肾脏疾病的影响, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=3826169024c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685625, encodeId=56211685625e1, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, objectTitle=JACC：PCSK9基因突变引起的低LDL与更低的心血管死亡风险相关, objectType=article, longId=172191, objectId=afd31e21917b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=afd31e21917b, replyNumber=0, likeNumber=106, createdTime=2020-04-30, rootId=0, userName=Tamikia, userId=173d28230918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=afd31e21917b, moduleTitle=JACC：PCSK9基因突变引起的低LDL与更低的心血管死亡风险相关, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=afd31e21917b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685621, encodeId=e383168562131, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, objectTitle=PCSK9抑制剂的专利纷争：美国陪审团支持安进的PCSK9抑制剂Repatha, objectType=article, longId=161338, objectId=7e7216133805, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e7216133805, replyNumber=0, likeNumber=80, createdTime=2019-07-10, rootId=0, userName=Tamikia, userId=173d28230918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e7216133805, moduleTitle=PCSK9抑制剂的专利纷争：美国陪审团支持安进的PCSK9抑制剂Repatha, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7e7216133805)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685622, encodeId=011c168562247, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, objectTitle=DIABETOLOGIA：MEDI4166，PCSK9抗体和GLP-1类似物融合分子在2型糖尿病超重或肥胖患者中研究, objectType=article, longId=163568, objectId=c531163568f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c531163568f7, replyNumber=0, likeNumber=75, createdTime=2019-07-09, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c531163568f7, moduleTitle=DIABETOLOGIA：MEDI4166，PCSK9抗体和GLP-1类似物融合分子在2型糖尿病超重或肥胖患者中研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c531163568f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685616, encodeId=951d16856167b, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, objectTitle=2018AHA热点持续升温！PCSK9抑制剂再添新证, objectType=article, longId=153437, objectId=9c2615343e4a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c2615343e4a, replyNumber=0, likeNumber=73, createdTime=2018-12-14, rootId=0, userName=Tamikia, userId=173d28230918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c2615343e4a, moduleTitle=2018AHA热点持续升温！PCSK9抑制剂再添新证, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=9c2615343e4a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685626, encodeId=f6ef16856260f, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, objectTitle=大剂量吗啡/舒芬太尼PCSA治疗难治性癌痛1例, objectType=article, longId=175492, objectId=52a01e5492ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52a01e5492ca, replyNumber=0, likeNumber=95, createdTime=2019-09-20, rootId=0, userName=Tamikia, userId=173d28230918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52a01e5492ca, moduleTitle=大剂量吗啡/舒芬太尼PCSA治疗难治性癌痛1例, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=52a01e5492ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685620, encodeId=82dd168562086, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, objectTitle=临床和经济评论研究所（ICER）：PCSK9抑制剂Alirocumab治疗高胆固醇症的证据更新, objectType=article, longId=160533, objectId=43881605336e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43881605336e, replyNumber=0, likeNumber=164, createdTime=2020-02-03, rootId=0, userName=Tamikia, userId=173d28230918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43881605336e, moduleTitle=临床和经济评论研究所（ICER）：PCSK9抑制剂Alirocumab治疗高胆固醇症的证据更新, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=43881605336e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PCS

2020-05-29

Tamikia (审核中...)

前往app查看评论内容

#PCS#

诺华与英国NHS联合，以快速推进胆固醇PCSK9的基因干扰药物inclisiran

2020-09-17

Tamikia (审核中...)

前往app查看评论内容

#PCS#

JAMA Cardiology：与他汀类药物和依折麦布相比，PCSK9抑制剂降低LDL-C的效果更显著

2021-04-20

Tamikia (审核中...)

前往app查看评论内容

#PCS#

Circulation：PCSK9抑制对静脉血栓栓塞（VTE）风险的影响

2021-04-23

Tamikia (审核中...)

前往app查看评论内容

#PCS#

诺华97亿收购的PCSK9的siRNA药物inclisiran，预计将于2020年批准上市

2020-10-24

Tamikia (审核中...)

前往app查看评论内容

#PCS#

JAHA：PCSK9抑制剂可改善HIV携带者冠脉健康

2021-01-19

Tamikia (审核中...)

前往app查看评论内容

#PCS#

Curr Atheroscle Rep：从机制到实践，PCSK9抑制剂成为降脂治疗新选择

2019-11-25

Tamikia (审核中...)

前往app查看评论内容

#PCS#

诺华宣布以97亿美元收购The Medicines Company，同时获得PCSK9的siRNA抑制剂

2020-03-29

Tamikia (审核中...)

前往app查看评论内容

#PCS#

Medicines公司的一年两次PCSK9抑制剂抗动脉粥样硬化达到III期研究的主要目标

2020-05-07

Tamikia (审核中...)

前往app查看评论内容

#PCS#

NEJM:PCSK9抑制剂 InclisiranIII期临床效果显著

2020-12-31

Tamikia (审核中...)

前往app查看评论内容

#PCS#

Clinica Chimica Acta：患有代谢综合征的绝经后妇女的循环PCSK9浓度出现增加?

2020-04-26

Tamikia (审核中...)

前往app查看评论内容

#PCS#

Neurology:“坏胆固醇LDL-C越低越好”受质疑，挑战PCSK9抑制剂安全性：Neurology杂志研究称，<70mg/dl脑出血风险增倍

2020-02-02

Tamikia (审核中...)

前往app查看评论内容

#PCS#

评估PCS-499治疗皮脂腺杆菌的安全性和耐受性

2019-08-30

Tamikia (审核中...)

前往app查看评论内容

#PCS#

Circulation：PCSK9抑制剂阿利库单抗对急性冠脉综合征患者卒中风险的影响

2020-10-28

Tamikia (审核中...)

前往app查看评论内容

#PCS#

JACC：PCSK9抑制剂对慢性肾脏疾病的影响

2019-07-16

Tamikia (审核中...)

前往app查看评论内容

#PCS#

JACC：PCSK9基因突变引起的低LDL与更低的心血管死亡风险相关

2020-04-30

Tamikia (审核中...)

前往app查看评论内容

#PCS#

PCSK9抑制剂的专利纷争：美国陪审团支持安进的PCSK9抑制剂Repatha

2019-07-10

爆笑小医 (审核中...)

前往app查看评论内容

#PCS#

DIABETOLOGIA：MEDI4166，PCSK9抗体和GLP-1类似物融合分子在2型糖尿病超重或肥胖患者中研究

2019-07-09

Tamikia (审核中...)

前往app查看评论内容

#PCS#

2018AHA热点持续升温！PCSK9抑制剂再添新证

2018-12-14

Tamikia (审核中...)

前往app查看评论内容

#PCS#

大剂量吗啡/舒芬太尼PCSA治疗难治性癌痛1例

2019-09-20

Tamikia (审核中...)

前往app查看评论内容

#PCS#

临床和经济评论研究所（ICER）：PCSK9抑制剂Alirocumab治疗高胆固醇症的证据更新

2020-02-03

科室
- - 订阅+
  - 更多科室
工具
服务